86604-75-3Relevant articles and documents
Syntheses and Crystal Structures of 2-Chloromethyl-3,5-dimethyl-4-methoxy/ethoxy-pyridines and Their Methylsulphinyl Derivatives
Ma, Sen,Chen, Min,Fan, Fang-Fang,Jia, Ai-Quan,Zhang, Qian-Feng
, p. 64 - 71 (2018)
Abstract: Treatment of 2-(chloromethyl)-pyridine derivatives 3,5-dimethyl-4-(alkoxy)-2-(chloromethyl)-pyridine hydrochloride (alkoxy = methoxy, 1; ethoxy, 2) with 1-(4-chloro-phenyl)imidazole-2-thione in the presence of sodium methoxide afforded the corresponding methylsulphinyl derivatives 3,5-dimethyl-[4-(alkoxy)-2-pyridinyl]-methylthio-1-(4-chloro-phenyl)-imidazole (alkoxy = methoxy, 3; ethoxy, 4). Similarly, reaction of 1 or 2 with 4,6-dimethyl-pyrimidine-2-thiol gave the methylsulphinyl derivatives 3,5-dimethyl-[4-(alkoxy)-2-pyridinyl]-methylthio-4,6-dimethyl-pyrimidine (alkoxy = methoxy, 5; ethoxy, 6). While reaction of 5 with CuCl2·2H2O in methanol produced a square-planar copper(II) complex, trans-bis{3,5-dimethyl-[4-(methoxy)-2-pyridinyl]-methylthio-4,6-dimethyl-pyrimidine}-dichloro-copper(II) (7). The crystal structures of 1, 2, 4?HCl?2H2O, and 7, along with their spectroscopic properties are reported. The weak hydrogen-bonding interactions exist in compounds 1, 2, and 4?HCl?2H2O. Compound 1 crystallizes in the monoclinic space group P21/c with a = 6.074(11), b = 19.88(4), c = 9.230(16)??, β = 99.67(4)°, and Z = 4. Compound 2 crystallizes in the monoclinic space group P21/n with a = 10.0103(15), b = 7.9905(12), c = 15.120(2) ?, β = 93.924(2), and Z = 4. The unit cells of both 4?HCl?2H2O and 7 have triclinic P-1 symmetry with the cell parameters a = 7.492(8), b = 10.170(12), c = 15.723(18) ?, α = 77.159(15)°, β = 91.113(13)°, γ = 81.194(16)°, and V = 1152(2)??3 for 4?HCl?2H2O and a = 10.526(2), b = 12.936(2), c = 14.455(3)??, α = 107.929(2)°, β = 93.686(2)°, γ = 104.095(3)°, and V = 1734.3(6) ?3 for 7. Graphical Abstract: Interaction of 3,5-dimethyl-[4-(methoxy)-2-pyridinyl]-methylthio-4,6-dimethyl-pyrimidine and CuCl2·2H2O in methanol resulted in the formation of a square-planar copper(II) complex, trans-bis{3,5-dimethyl-[4-(methoxy)-2-pyridinyl]-methylthio-4,6-dimethyl-pyrimidine}-dichloro-copper(II), which was structurally characterized.
Synthesis method of omeprazole intermediate
-
Paragraph 0021; 0023-0029, (2020/07/13)
The invention relates to a synthesis method of an omeprazole intermediate, in particular to a synthesis method of an omeprazole intermediate. According to the technical scheme, the synthesis method ischaracterized in that 3, 5-dimethyl-4-nitropyridine-N-oxide is used as an initial raw material, and 2-chloromethyl-3, 5-dimethyl-4-methoxypyridine is obtained through a methoxylation reaction, a methylation reaction, a rearrangement reaction and a chlorination reaction. The synthesis method of the omeprazole intermediate is high in yield, and the yield can reach 78.9%.
Preparation method of omeprazole intermediate
-
Paragraph 0063-0064; 0066; 0067-0068; 0070; 0071-0072; 0074, (2021/01/15)
The invention relates to a preparation method of an omeprazole intermediate. According to the method, Nmethoxy-4-methoxy3, 5-dimethyl pyridinium is used as a raw material, metal ions are added as an additive, under the action of persulfate, 2-hydroxymethyl- 3, 5-dimethyl -4methoxypyridine is efficiently prepared, and then the 2-hydroxymethyl -3, 5-dimethyl- 4-methoxypyridine is further converted into 2-chloromethyl -3, 5-dimethyl- 4methoxypyridine hydrochloride. According to the method, the conversion rate, the yield and the quality of the 2-hydroxymethyl- 3, 5-dimethyl -4-methoxy pyridine areremarkably improved, so that the purity of the 2-chloromethyl- 3, 5-dimethyl- 4-methoxy pyridine hydrochloride obtained by further reaction is improved, the impurity content is reduced, the product yield and the production efficiency can be effectively improved, the production capacity is improved, and the production cost is reduced.
Preparation method of omeprazole midbody
-
Paragraph 0084-0087, (2019/10/22)
The invention relates to a preparation method of 2-chloromethyl-3,5-dimethyl-4-methoxypyridine shown in a chemical structural formula I. The method is characterized by comprising the steps of a catalytic hydrogenation reaction, wherein Raney nickel or Pd/C is selected as a catalyst; a chlorination reaction, wherein YCln is selected from N-chloroacetamides or N-chlorosuccinimide or 1,3-dichloro-5,5-dimethylhydantoin or dichlord isocyanurice acid or symclosene; n is selected from 3 or 2 or 1; m is selected from 0 or 1 or 2.
Esomeprazole sodium and lyophilized preparation comprising same
-
Paragraph 0038; 0039; 0040, (2019/03/28)
The invention provides esomeprazole sodium and a lyophilized preparation comprising the same. A preparation method of esomeprazole sodium includes following steps: 1), synthesizing an intermediate; 2), synthesizing esomeprazole sodium; 3), roughly preparing esomeprazole sodium; 4), finely preparing esomeprazole sodium. Esomeprazole sodium prepared by the method is higher in preparation accuracy and safer to use; the preparation process is easier to control, and step decomposition brings convenience to quality control of middle steps, so that ensuring of preparation accuracy of esomeprazole sodium is facilitated, and drug prepared from esomeprazole sodium is safer.
Method for preparing high-purity razole intermediate and medicine by using green technology instead of phosgene, thionyl chloride and other toxic and harmful substances
-
Paragraph 0063; 0064; 0066; 0068; 0072; 0074, (2017/09/01)
The invention discloses a method for preparing a high-purity razole intermediate and a medicine by using a green technology instead of phosgene, thionyl chloride and other toxic and harmful substances. The preparation method comprises the following steps: dissolving Ph3PO in an organic solvent, placing the obtained solution in a reaction bottle, dropwise adding BTC to form a high-efficiency chloration reagent, carrying out a heat insulation reaction for a period of time after the dropwise addition is finished, dissolving a razole hydroxide in the organic solvent, dropwise adding the obtained solution to the above system, carrying out a heat insulation reaction for a period of time, carrying out suction filtration, and drying the obtained dried reaction product to obtain razole chloride. In the process, the Ph3PO is equivalently regenerated, a mother liquor part is concentrated to precipitate the Ph3PO at a low temperature, and the Ph3PO can be repeatedly used after being washed with a solvent with small polarity. The method has the advantages of few side reactions, high product quality, few "three wastes" pollutions, high atomic economy, and good promotion and application prospect. The invention also provides a relevant razole medicine prepared from the razole chloride obtained through the green technology. The medicine has obviously higher purity than medicines obtained through traditional methods.
Diversified synthesis of novel quinoline and dibenzo thiazepine derivatives using known active intermediates
Sharada,Satyanarayana Reddy,Sammaiah,Sumalatha
, p. 7959 - 7966 (2013/09/23)
The novel drug development to control resisting infections in conventional drug therapy is a need of today. Few antiulcer relative derivatives developed by approaching convergent synthesis. The derivatives synthesized successfully are dibenzo thiazepine-pyridine (SLN11-SLN15) and benzimidazole-hydroquinoline based derivatives (SLN16-SLN20). It involved the coupling through microwave, sonication and conventional techniques at final step. The efficient technology identified as sonication technique basically time and yield. The reported compounds were structural characterized by elemental analysis and spectral studies such as 1H, 13C NMR and MS.
PROCESS FOR THE PREPARATION OF ESOMEPRAZOLE MAGNESIUM DIHYDRATE
-
Page/Page column 19-20, (2008/12/08)
A process for preparing Form A of (S)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)- methyl]sulfinyl]-1 H-benzimidazole magnesium dihydrate, processes for preparing various intermediates useful in the preparation of Form A of (S)-5-methoxy-2-[[(4-methoxy-3,5- dimethyl-2-pyridinyl)-methyl]sulfinyl]-1 H-benzimidazole magnesium dihydrate and a novel polymorphic Form II of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]thio]-1 H- benzimidazole.
Process for preparing isomerically pure prodrugs of proton pump inhibitors
-
Page/Page column 6, (2010/02/10)
Synthetic methods for preparing isomerically pure N-arylsulfonyl derivatives of proton pump inhibitors which include a substituted benzimidazole nucleus are shown by the synthetic schemes and experimental description.
PRODRUGS OF PROTON PUMP INHIBITORS
-
Page 156, (2010/02/06)
Prodrugs of proton pump inhibitors of Formulas 1 through 4, (I-IV), where the symbols are as defined in the specification, and the R group includes at least one acidic group or its pharmaceutically acceptable salt, have improved aqueous solubility and bioavailability.
